ConductScience.org, home

Paper41681925

The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System.

Wendler J and 11 others. Cancers (Basel), 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System. Papers, record 41681925. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41681925

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-02-16
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wendler JJuliahttps://orcid.org/0000-0002-0088-1915
2Kasenda BBenjamin
3Lauer EMEliza Mhttps://orcid.org/0000-0002-2992-7868
4Kama KKudrethttps://orcid.org/0000-0002-0175-9823
5Isbell LKLisa Kristinahttps://orcid.org/0000-0002-9119-4589
6Marschner DDominikhttps://orcid.org/0009-0003-1639-8762
7Scherer FFlorian
8Malenica NNatalie
9Gloggengiesser CCora
10Valk EElke
11Schorb EElisabethhttps://orcid.org/0000-0003-0948-2125
12Illerhaus GGerald

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
n.a.AbbVie (Germany)PubMed
n.a.Roche Pharma AG (Germany)PubMed

Source PubMed

Download CSV of grants

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137215448Venetoclax Penetrates the Blood Brain Barrier: A Pharmacokinetic Analysis in Pediatric Leukemia Patients.J Cancer2023https://conductscience.org/library/papers/37215448PubMed
226239089Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.Blood2015https://conductscience.org/library/papers/26239089PubMed
335562406Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.Leukemia2022https://conductscience.org/library/papers/35562406PubMed
438836097Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Hemasphere2024https://conductscience.org/library/papers/38836097PubMed
527132696
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Lancet Haematol2016https://conductscience.org/library/papers/27132696PubMed
627407096Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.Clin Cancer Res2016https://conductscience.org/library/papers/27407096PubMed
728325865Venetoclax and obinutuzumab in chronic lymphocytic leukemia.Blood2017https://conductscience.org/library/papers/28325865PubMed
824346116Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.Cancer Discov2014https://conductscience.org/library/papers/24346116PubMed
925916698Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.Leuk Res2015https://conductscience.org/library/papers/25916698PubMed
1035004280Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series.Front Oncol2021https://conductscience.org/library/papers/35004280PubMed
1135732829The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.Leukemia2022https://conductscience.org/library/papers/35732829PubMed
1237322012Primary central nervous system lymphoma.Nat Rev Dis Primers2023https://conductscience.org/library/papers/37322012PubMed
1333560416Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).Neuro Oncol2021https://conductscience.org/library/papers/33560416PubMed
1412393404Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment.Blood2003https://conductscience.org/library/papers/12393404PubMed
1538301670High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial.Lancet Haematol2024https://conductscience.org/library/papers/38301670PubMed
1634699590Primary central nervous system lymphoma.Blood2022https://conductscience.org/library/papers/34699590PubMed
1732583848Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.Neuro Oncol2021https://conductscience.org/library/papers/32583848PubMed
1839286959Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patients.Clin Transl Sci2024https://conductscience.org/library/papers/39286959PubMed
1930698644
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ann Oncol2019https://conductscience.org/library/papers/30698644PubMed
2029986852Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.Blood Adv2018https://conductscience.org/library/papers/29986852PubMed

See all 26 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
KRT2054474PubTator's text mininghttps://conductscience.org/library/genes/54474NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41681925

GET https://conductscience.org/api/papers/v1/41681925/references?page=2